PL356387A1 - Sposoby wytwarzania kompozycji farmaceutycznych oprzedłużonym uwalnianiu alkaloidów sporyszu o większej biodostępności i ich kompozycje - Google Patents

Sposoby wytwarzania kompozycji farmaceutycznych oprzedłużonym uwalnianiu alkaloidów sporyszu o większej biodostępności i ich kompozycje

Info

Publication number
PL356387A1
PL356387A1 PL00356387A PL35638700A PL356387A1 PL 356387 A1 PL356387 A1 PL 356387A1 PL 00356387 A PL00356387 A PL 00356387A PL 35638700 A PL35638700 A PL 35638700A PL 356387 A1 PL356387 A1 PL 356387A1
Authority
PL
Poland
Prior art keywords
compositions
bioavailability
sustained
methods
ergot
Prior art date
Application number
PL00356387A
Other languages
English (en)
Other versions
PL202357B1 (pl
Inventor
Federico Mailland
Original Assignee
Polichem S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem S.A. filed Critical Polichem S.A.
Publication of PL356387A1 publication Critical patent/PL356387A1/pl
Publication of PL202357B1 publication Critical patent/PL202357B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL356387A 1999-12-03 2000-11-30 Kompozycja farmaceutyczna o przedłużonym uwalnianiu PL202357B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45436499A 1999-12-03 1999-12-03
PCT/EP2000/012302 WO2001039742A2 (en) 1999-12-03 2000-11-30 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof

Publications (2)

Publication Number Publication Date
PL356387A1 true PL356387A1 (pl) 2004-06-28
PL202357B1 PL202357B1 (pl) 2009-06-30

Family

ID=23804314

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356387A PL202357B1 (pl) 1999-12-03 2000-11-30 Kompozycja farmaceutyczna o przedłużonym uwalnianiu

Country Status (17)

Country Link
US (1) US20020114836A1 (pl)
EP (2) EP1235574B1 (pl)
JP (1) JP4965784B2 (pl)
KR (1) KR100504618B1 (pl)
CN (1) CN100400042C (pl)
AT (1) ATE288269T1 (pl)
AU (1) AU2165301A (pl)
BR (1) BR0016084A (pl)
CA (1) CA2393344C (pl)
DE (1) DE60017938T2 (pl)
ES (1) ES2236017T3 (pl)
HK (1) HK1048254B (pl)
MX (1) MXPA02005291A (pl)
PL (1) PL202357B1 (pl)
PT (1) PT1235574E (pl)
RU (1) RU2256454C2 (pl)
WO (1) WO2001039742A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518734A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
WO2005044262A1 (en) 2003-10-29 2005-05-19 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
JP5228488B2 (ja) * 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
CN101590058B (zh) * 2009-07-02 2011-04-27 苏州东瑞制药有限公司 含有甲磺酸二氢麦角隐亭a的药物组合物
EP3980001B1 (en) * 2019-06-10 2025-08-27 Ponce de Leon Health Designated Activity Company Sustained-release compositions of alpha-ketoglutarate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
BE880713A (fr) * 1978-12-21 1980-06-19 Sandoz Sa Nouvelles compositions pharmaceutiques solides a base d'alcaloides de l'ergot de seigle, permettant une liberation controlee de ce principe actif
JPS615010A (ja) * 1984-06-18 1986-01-10 Tooa Eiyoo Kk 水素添加麦角アルカロイド徐放性製剤及びその製法
NL8600161A (nl) * 1985-02-05 1986-09-01 Sandoz Ag Farmaceutische preparaten die 9,10-dihydroergotalkaloiden bevatten.
JPS62221626A (ja) * 1986-03-20 1987-09-29 Tokyo Tanabe Co Ltd １，４−ジヒドロピリジン化合物の製剤用組成物
FR2610827B1 (fr) * 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
YU47044B (sh) * 1987-03-11 1994-12-28 LEK TOVARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOV n.sol.o. Postupak za dobijanje tableta sa produženim delovanjem na bazi hidroksipropil-metilceluloze velike molekularne mase
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications

Also Published As

Publication number Publication date
WO2001039742A3 (en) 2001-12-13
EP1235574A2 (en) 2002-09-04
EP1512403A1 (en) 2005-03-09
PL202357B1 (pl) 2009-06-30
CA2393344A1 (en) 2001-06-07
CN100400042C (zh) 2008-07-09
HK1048254B (en) 2005-06-03
CA2393344C (en) 2009-09-01
WO2001039742A2 (en) 2001-06-07
BR0016084A (pt) 2002-08-06
RU2002117655A (ru) 2004-01-27
EP1235574B1 (en) 2005-02-02
KR20020063197A (ko) 2002-08-01
MXPA02005291A (es) 2004-06-21
AU2165301A (en) 2001-06-12
HK1048254A1 (en) 2003-03-28
ATE288269T1 (de) 2005-02-15
KR100504618B1 (ko) 2005-08-04
ES2236017T3 (es) 2005-07-16
CN1433311A (zh) 2003-07-30
US20020114836A1 (en) 2002-08-22
DE60017938D1 (de) 2005-03-10
JP4965784B2 (ja) 2012-07-04
JP2003515549A (ja) 2003-05-07
RU2256454C2 (ru) 2005-07-20
DE60017938T2 (de) 2006-01-12
PT1235574E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
EP0915701B1 (en) Fast-dissolving galanthamine hydrobromide tablet
CA1147651A (en) Sustained release pharmaceutical compositions
EP1017391B1 (en) Sustained release tablet formulation to treat parkinson disease
AU684053B2 (en) Compositions of L-DOPA esters
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
US4724148A (en) Amosulalol hydrochloride long acting formulation
AU2165301A (en) Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2216277A1 (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
NO173736C (no) Analogifremgangsmaate for fremstilling av en terapeutisk aktiv forbindelse bestaaende hovedsaklig av diastereomer (I) av cefalosporinderivater
CA2135179A1 (en) Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration
PL328123A1 (en) Derivatives of banzo[c]quinolysine and method of obtaining them
WO2024144207A1 (en) Sustained-release tablet comprising apixaban
WO2019245309A1 (en) A sustained release pharmaceutical preparation comprising tacrolimus
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
DK0524696T3 (da) Orale præparater indeholdende dapiprazol
JP2003515549A5 (pl)
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
SE9600791L (sv) Metod för eradikering av Helicobacter pylori infektion
HUP0202229A2 (hu) Orális folyékony gyógyszerkészítmények, amelyek kinolonszármazékokat és ízelfedőként ioncserélő gyantákat tartalmaznak
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
MX9601033A (es) Nanosuspensiones para administracion intravenosa.